netFormulary The Pennine Acute Hospitals NHS
NHS Trust Formulary  
 Search
 Formulary Chapter 10: Musculoskeletal and joint diseases - Full Chapter
10.01.01  Expand sub section  Non-steroidal anti-inflammatory drugs
Ibuprofen
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice Tablets
Oral suspension
5% gel 
Naproxen
View adult BNF View SPC online View childrens BNF  Track Changes
Second Choice Tablets 
   
Etoricoxib (Arcoxia®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Tablets 
Link  MHRA Safety Update: Revised dosing recommendations
   
Celecoxib (Celebrex®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Capsules 
   
Diclofenac
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted Suppositories
Injection


Restricted Item Diclofenac is contraindicated in patients with established:

•ischaemic heart disease
•peripheral arterial disease
•cerebrovascular disease
•congestive heart failure (New York Heart Association [NYHA] classification II–IV)

Diclofenac treatment should only be initiated after careful consideration for patients with significant risk factors for cardiovascular events (eg, hypertension, hyperlipidaemia, diabetes mellitus, smoking).

 
Link  MHRA Drug Safety Update: Diclofenac contraindications and warnings
   
Etodolac
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Capsules
Modified release tablets 
   
Indometacin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Capsules
Modified-release capsules
Suppositories
 
   
Mefenamic Acid
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Capsules
Tablets
Oral suspension 
   
Meloxicam
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Tablets 
   
Nabumetone
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Tablets
Oral suspension 
   
 ....
 Non Formulary Items
Acelofenac  (Preservex®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Acemetacin  (Emflex®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Azapropazone  (Rheumox®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Dexibuprofen  (Seractil®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Dexketoprofen  (Keral®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Diclofenac

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary Tablets
Dispersible tablets
Modified-Release Capsules/Tablets

Diclofenac is contraindicated in patients with established:

•ischaemic heart disease
•peripheral arterial disease
•cerebrovascular disease
•congestive heart failure (New York Heart Association [NYHA] classification II–IV)
Patients with these conditions should be switched to an alternative treatment at their next routine appointment.

Link  MHRA Drug Safety Update June 2013: Diclofenac Cardiovascular Safety
Link  MHRA Drug Safety Update October 2012: Diclofenac Cardiovascular Risk
 
Diclofenac with Misoprostol  (Arthrotec 50 and 75®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary Tablets
Link  MHRA Drug Safety Update June 2013: Diclofenac Cardiovascular Safety
Link  MHRA Drug Safety Update October 2012: Diclofenac Cardiovascular Risk
 
Fenbufen

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Fenoprofen  (Fenopron®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Flurbiprofen

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ibuprofen and famotidine  (Duexis®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ketoprofen

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Lumiracoxib  (Prexige®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Naproxen & esomeprazole  (Vimovo®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Naproxen with Misoprostol  (Napratec®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Piroxicam

View adult BNF View SPC online View childrens BNF
Non Formulary
Link  CHMP advice June 2007: Restricted use of piroxicam
 
Sulindac

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
 
Tenoxicam  (Mobiflex®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Tiaprofenic Acid

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Drugs designated amber are suitable for shared care arrangements under a shared care protocol. Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.   

Black

These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products.  

Green

Not used   

Green 1

Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care.   

Green 2

Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required.  

Green 3

Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required.  

Grey

Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient.   

Red

Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.   

netFormulary